Ignite Creation Date:
2024-05-06 @ 6:56 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05838170
Status:
COMPLETED
Last Update Posted:
2023-11-24
First Post:
2023-03-13
Brief Title:
Study of TP-04 in Participants With Papulopustular Rosacea
Sponsor:
Tarsus Pharmaceuticals Inc
Organization:
Tarsus Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Vehicle-Controlled Parallel-Group Study Evaluating the Safety Tolerability and Efficacy of TP-04 in Participants With Papulopustular Rosacea
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to evaluate the safety tolerability and efficacy of the study drug TP-04 in participants with papulopustular rosacea PPR
Detailed Description:
This is a Phase 2 multicenter randomized double-blind parallel-group vehicle-controlled study evaluating the safety tolerability and efficacy of Lotilaner Gel 20 TP-04 applied BID for 12 weeks in participants with moderate to severe PPR
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None